Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors.
Gülin Alkan ŞenNihan Şentürk ÖztaşEzgi DeğerliMurad GuliyevGünay CanHande TurnaMustafa ÖzgüroğluPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)
Our findings demonstrated that HPD was a rapid phenomenon with significantly poor survival rates. Several clinicopathological factors and tumor characteristics might indicate HPD.